The short version. We have directed one IV therapy practice for more than seven years. That is the part worth
reading: not the launch, but what a directorship has to absorb over time as the menu grows, the
staff turns over, and the marketing rules move underneath the business.
What this is. A real MDside engagement, described without naming the client. No client name, location, ownership or commercial terms appear here, and nothing below identifies the practice. It is not a client case study and it is not a testimonial: the client has not endorsed us and is not quoted. The regulatory points are cited at the foot of the page.
Why tenure is the measurement that matters
A medical directorship is easy to enter and easy to fake. Its quality shows up over years, in whether the protocols were revised when the menu changed, whether the person named on the agreement was reachable when something went wrong, and whether the documentation would survive a records request from a Board that has decided to look.
The failure mode is well documented and we have published it: a director paid monthly, told he need not attend, unaware of who he was supervising. The opposite of that is not a stronger contract. It is a relationship that is still in place, and still active, years later.
What stayed constant
- An order behind every bag. IV therapy is the practice of medicine. Someone licensed has to evaluate the patient and order the infusion, and that has not changed in seven years in any state.
- Standing orders that match the menu, reviewed when the menu changes rather than when someone remembers.
- A named physician with real authority over what the practice offers and what it declines to offer.
What changed, and had to be handled
- The menu grew. Additions like NAD+ carry their own requirements — a provider order, a protocol specifying infusion rate, and documented sourcing. Each addition is a protocol revision, not a price-list update.
- Staff turned over. Every new nurse changes who is delegated what, and delegation documentation that names people has to be maintained as those people change.
- Marketing claims drifted. This is the recurring one. Wellness copy tends toward therapeutic claims over time, and the director is the person who has to say which claims the practice cannot make.
- Compounding rules moved. Sourcing decisions that were unremarkable in one year required a different answer in another.
What an operator should take from this
- Ask a prospective director what they did in year three of an engagement, not what they will do in month one.
- Budget for protocol maintenance. A menu that grows without protocol revision is the gap an adverse event finds.
- Treat your website as clinical documentation. It is the first thing anyone reads and the easiest thing to get wrong.
Read next
Frequently asked questions
How often should protocols be reviewed?
On change, and on a schedule. Any new service, device or sourcing decision triggers a review; absent changes, an annual review keeps the documentation current and dated.
Does IV therapy really need a medical director?
It needs an ordering provider standing behind the infusion, and in most structures that authority sits with a named medical director. The requirement follows the medicine, not the branding.
What most often goes wrong over time?
Marketing claims. The menu and the protocols usually keep pace with each other; the website is what drifts.
Sources. General IV therapy requirements: an ordering provider, standing orders matched to the menu, and documented sourcing. Engagement details are generalised, no dates that identify the practice are given, and no client is identified.
General information, not legal advice. This page describes a real engagement without identifying the client. Confirm your own position with healthcare counsel licensed where you operate.